Author: Ravi Shankar

• Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab’s potential to be a transformational therapy in CSU
• EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups
• Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema
• Efficacy sustained or deepened from weeks 12 to 24
• Well tolerated with a favorable safety profile through 24 weeks; consistent with prior studies
• Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027
• Company to host webcast today at 8:00 am ET

HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. The EMBARQ-CSU1 and EMBARQ-CSU2 studies are the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU. Both Phase 3 trials met the primary endpoint of mean change from baseline in weekly urticaria activity score (UAS7) at Week 12, and all key secondary endpoints, demonstrating clinically meaningful and statistically significant improvements in disease activity. Barzolvolimab was well-tolerated through the 24 week placebo controlled treatment period with a favorable safety profile consistent with prior Phase 2 experience. The EMBARQ-CSU trials are ongoing, with treatment continuing through 52 weeks. The Company intends to present the EMBARQ-CSU data at an upcoming medical meeting and plans to submit a Biologics License Application (BLA) to the FDA in 2027.

“We are proud of the results shared today and believe that barzolvolimab has the potential to address the enormous unmet need in CSU,” said Diane Young, MD, Senior Vice President and Chief Medical Officer of Celldex. “Barzolvolimab continued to show unprecedented complete response rates across the overall studies and demonstrated strong differentiation in patient populations underserved by existing therapies, including those with severe disease or angioedema, and those whose disease is refractory to omalizumab. We believe that barzolvolimab can be a transformational therapy for people living with CSU and thank the CSU community, trial participants, and investigators around the world for their support of the EMBARQ-CSU trials and the entire barzolvolimab clinical program.”

“The results from our two Phase 3 EMBARQ-CSU trials showed efficacy that is best-in-disease in CSU,” said Anthony Marucci, Co-Founder, President, and Chief Executive Officer at Celldex. “We believe barzolvolimab is well-positioned to address large CSU populations of high unmet need—as a first-line therapy for patients with severe CSU or angioedema, and as the second-line advanced therapy of choice. We look forward to continuing to grow our leadership in mast cell biology as we advance to our next stage of development—establishing a commercial-stage organization committed to delivering barzolvolimab to patients and physicians in need as quickly as possible.”

Summary of Key Findings
Data cutoff: September 9, 2026

The Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies demonstrated rapid, profound, sustained efficacy consistent with Phase 2 and unparalleled in CSU. Efficacy was sustained or deepened from weeks 12 to 24 across primary and all key secondary endpoints

Primary Endpoint: Mean Change from Baseline in UAS7 at Week 12:
	EMBARQ-CSU1		EMBARQ-CSU2
	Baseline UAS7	LS Mean Change (SE) at Week 12	Baseline UAS7	LS Mean Change (SE) at Week 12
Placebo	30.9	-10.7 (0.65)	29.3	-11.4 (0.64)
150 mg Q4W	30.6	-20.2 (0.64) (p<.00001)	29.7	-20.2 (0.63) (p<.00001)
300 mg Q8W	30.3	-20.5 (0.65) (p<.00001)	29.6	-19.7 (0.64) (p<.00001)

P-values are for LS Mean treatment difference versus placebo.

• The primary endpoint showed clinically meaningful and highly statistically significant improvement.

Key Secondary Endpoints: All key secondary endpoints in both EMBARQ-CSU trials were met at Week 12 with high statistical significance and were clinically meaningful.

Given the importance of Complete Response (complete absence of itch and hives) to patients and physicians, and barzolvolimab’s unique ability to drive sustained Complete Response, the Company is presenting UAS7=0 data observed at both 12 and 24 weeks.

Proportion of Patients with Complete Response (UAS7=0) at Weeks 12 and 24
	EMBARQ-CSU1	EMBARQ-CSU2
	12 Weeks
Placebo	9.3%	12.6%
150 mg Q4W	42.4% (p<.00001)	45.7% (p<.00001)
300 mg Q8W	42.1% (p<.00001)	44.0% (p<.00001)
	24 Weeks
Placebo	15.4%	17.6%
150 mg Q4W	49.0% (p<.00001)	54.0% (p<.00001)
300 mg Q8W	45.1% (p<.00001)	48.4% (p<.00001)

P-values are based on adjusted odds ratio of logistic regression models.

• Significantly more patients achieved Complete Response (UAS7=0) with both barzolvolimab doses vs. placebo at Weeks 12 and 24.

Proportion of Patients with Complete Response (UAS7=0) at Week 12 in Omalizumab-Refractory CSU
	EMBARQ-CSU1	EMBARQ-CSU2
Placebo	9.3%	15.1%
150 mg Q4W	55.3% (p<.00001)	41.7% (p=.0089)
300 mg Q8W	44.3% (p=.00017)	46.4% (p=.0036)

P-values are based on adjusted odds ratio of logistic regression models.

• A higher proportion of patients achieved Complete Response (UAS7=0) vs placebo at Week 12 in the sub-population of patients with CSU refractory to omalizumab.

Proportion of Patients with AAS7=0 at Week 12 in Patients with Baseline AAS7>0
	EMBARQ-CSU1	EMBARQ-CSU2
Placebo	33.8%	33.7%
150 mg Q4W	62.7% (p<.00001)	74.3% (p<.00001)
300 mg Q8W	66.3% (p<.00001)	66.2% (p<.00001)

P-values are based on adjusted odds ratio of logistic regression models.

• A statistically higher proportion of patients achieved complete resolution of angioedema (AAS7=0) at Week 12 vs. placebo in patients with baseline AAS7>0.

Barzolvolimab was well-tolerated and demonstrated a favorable safety profile consistent with prior experience through the end of the placebo controlled period at Week 24.

The Phase 3 EMBARQ-CSU1 and CSU2 studies are ongoing. A BLA submission is planned for 2027.

The Phase 3 Program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. Both Phase 3 trials are randomized, double-blind, placebo-controlled, parallel group, global studies. 1,939 patients were randomized (n=963 EMBARQ-CSU1; n=976 EMBARQ-CSU2) evenly to barzolvolimab 150 mg every 4 weeks (following 300 mg loading dose), barzolvolimab 300 mg every 8 weeks (following 450 mg loading dose) for 52 weeks or placebo for 24 weeks. At 24 weeks, patients on placebo were re-randomized to active treatment across both dosing groups. The primary endpoint of the study evaluated the clinical effect of barzolvolimab in reducing urticaria activity (weekly urticaria activity score; UAS7) at Week 12. The studies were designed to detect a clinically meaningful difference between each of the active arms vs placebo in the overall population as well as in the subpopulation of omalizumab refractory participants. The primary endpoint analysis was performed when all patients completed the placebo controlled portion of the study at 24 weeks. A global Phase 3b long term extension study (LTE) has been established and is ongoing, which patients can enter following completion of the EMBARQ-CSU Phase 3 trials.

Please visit clinicaltrials.gov for additional information on EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202.

Webcast and Conference Call
The Company will host a conference call/webcast today to discuss the results at 8:00am ET. To access the live and archived webcast, please visit the Events section on the Investor Relations page of Celldex’s website. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call. Otherwise, please access the listen-only webcast link. The archived webcast will be available for a limited time on the Company’s website.

About Barzolvolimab
Barzolvolimab is a humanized monoclonal antibody with a novel mechanism of action that targets mast cells by binding with high specificity to a unique part of the KIT receptor and potently inhibiting its activity. The KIT receptor is abundantly expressed by mast cells and critical for their function and survival. Mast cells are drivers of inflammatory responses such as hypersensitivity and allergic reactions and, in certain inflammatory diseases, such as chronic urticarias, mast cell activation plays a central role in the onset and progression of the disease. Based on data from robust, randomized, placebo controlled Phase 2 studies, barzolvolimab has significant potential as a first-in-class and best-in-disease treatment option for patients with chronic spontaneous urticaria (CSU), cold urticaria (ColdU) and symptomatic dermographism (SD). Barzolvolimab is currently being studied in Phase 3 studies in CSU and ColdU/SD and a Phase 2 study in atopic dermatitis (AD), with additional indications planned for the future.

About Celldex
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com.

Forward Looking Statement
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159) and CDX-622, in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals, including the Company’s plan to submit a BLA in 2027; the failure of the market for the Company’s programs to continue to develop; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under “Risk Factors“ in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com

Elizabeth Higgins
Executive Director, Investor Relations & Corporate Communications
(857) 404-2088
ehiggins@celldex.com

MEMPHIS, Tenn., Sept. 22, 2026 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today reported net sales of $6.6 billion for its fourth quarter (16 weeks) ended August 29, 2026, an increase of 5.6% from the fourth quarter of fiscal 2025 (16 weeks). Same store sales, or sales for our domestic and international stores open at least one year, are as follows:

					Constant Currency							Constant Currency
	16 Weeks				16 Weeks*			52 Weeks				52 Weeks*
Domestic	1.6	%			1.6	%		3.3	%			3.3		%
International	10.7	%			1.3	%		13.5	%			2.2		%
Total Company	2.7	%			1.5	%		4.5	%			3.2		%
* Excludes impacts from fluctuations of foreign exchange rates.

For the quarter, gross profit, as a percentage of sales, was 53.3%, an increase of 182 basis points versus the prior year. The increase in gross margin was driven by a 145 basis point impact from tariff refunds and a 105 basis point net non-cash LIFO impact, partially offset by higher commercial mix. Operating expenses, as a percentage of sales, were 33.4% versus last year at 32.4% with deleverage primarily driven by growth initiatives.

Operating profit increased 10.1% to $1.3 billion. Net income for the quarter was $931.6 million compared to $837.0 million in the same period last year, while diluted earnings per share were $56.05 compared to last year at $48.71.

For the fiscal year ended August 29, 2026, net sales were $20.3 billion, an increase of 7.4% from the prior year. Gross profit, as a percentage of sales, was 52.3% versus last year at 52.6%. The decrease in gross margin was impacted by a 61 basis point net non-cash LIFO impact, partially offset by a 48 basis point benefit from tariff refunds. Operating expenses, as a percentage of sales, were 34.0% versus last year at 33.6%. Operating profit increased 3.1% to $3.7 billion, net income increased 3.0% to $2.6 billion and diluted earnings per share increased 5.3% to $152.55 from $144.87.

Under its share repurchase program, AutoZone repurchased 223 thousand shares of its common stock at an average price per share of $3,125, for a total investment of $697.5 million. For the fiscal year, the Company repurchased 579 thousand shares of its common stock, at an average price of $3,496, for a total investment of $2.0 billion. At year end, the Company had $1.6 billion remaining under its current share repurchase authorization.

The Company’s inventory increased 10.1% over the same period last year, driven primarily by growth initiatives. Net inventory, defined as merchandise inventories less accounts payable, on a per store basis, was negative $107 thousand versus negative $131 thousand last year and negative $107 thousand last quarter.

“I want to thank our entire organization for delivering another quarter of sales and earnings growth. In spite of a difficult selling environment the first eight weeks of our quarter, we remained committed to executing on our strategies to grow both our domestic and international businesses. Over the last eight weeks of the quarter our sales results strengthened, and we feel we are well positioned for sales growth in fiscal 2027.  We opened 175 new stores this past quarter, which included 16 new Mega Hub stores in the U.S. We continue to improve our inventory offering for both the do-it-yourself and professional customers. We continue to improve our speed of delivery and are intently focused on exceptional customer service. Based on the data we have, we continued to gain share and we expect sales in each of the three countries in which we operate to accelerate in the new fiscal year.  As always, we will remain committed to a disciplined approach of driving shareholder value,” said Phil Daniele, President and Chief Executive Officer.

During the quarter ended August 29, 2026, AutoZone opened 97 new stores in the U.S., 68 in Mexico and 10 in Brazil for a total of 175 new stores. For the fiscal year, the Company opened 374 new stores. As of August 29, 2026, the Company had 6,863 stores in the U.S., 1,001 in Mexico and 167 in Brazil for a total store count of 8,031.

AutoZone is a leading retailer and distributor of automotive replacement parts and accessories in the Americas. Each store carries an extensive product line for cars, sport utility vehicles, vans and light duty trucks, including new and remanufactured automotive hard parts, maintenance items, accessories, and non-automotive products. The majority of stores have a commercial sales program that provides prompt delivery of parts and other products and commercial credit to local, regional and national repair garages, dealers, service stations, fleet owners and other accounts. AutoZone also sells automotive hard parts, maintenance items, accessories and non-automotive products through www.autozone.com, and our commercial customers can make purchases through www.autozonepro.com. Additionally, we sell the ALLDATA brand of automotive diagnostic, repair, collision and shop management software through www.alldata.com. We also provide product information on our Duralast branded products through www.duralastparts.com. AutoZone does not derive revenue from automotive repair or installation services.

AutoZone will host a conference call this morning, Tuesday, September 22, 2026, beginning at 10:00 a.m. (ET) to discuss its fourth quarter results. This call is being webcast and can be accessed, along with supporting slides, at AutoZone’s website at www.autozone.com by clicking on Investor Relations. Investors may also listen to the call by dialing (888) 506-0062, passcode AUTOZONE. In addition, a telephone replay will be available by dialing (877) 481-4010, replay passcode 54424 through October 20, 2026.

This release includes certain financial information not derived in accordance with generally accepted accounting principles (“GAAP”). These non-GAAP measures include adjustments to reflect return on invested capital, adjusted debt and adjusted debt to earnings before interest, taxes, depreciation, amortization, rent and share-based expense (“EBITDAR”). The Company believes that the presentation of these non-GAAP measures provides information that is useful to investors as it indicates more clearly the Company’s comparative year-to-year operating results, but this information should not be considered a substitute for any measures derived in accordance with GAAP. Management targets the Company’s capital structure in order to maintain its investment grade credit ratings. The Company believes this is important information for the management of its debt levels and share repurchases. We have included a reconciliation of this additional information to the most comparable GAAP measures in the accompanying reconciliation tables.

Certain statements herein constitute forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically use words such as “believe,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “seek,” “may,” “could” and similar expressions. These statements are based on assumptions and assessments made by our management in light of experience, historical trends, current conditions, expected future developments and other factors that we believe appropriate. These forward-looking statements are subject to a number of risks and uncertainties, including without limitation: product demand, due to changes in fuel prices, miles driven or otherwise; energy prices; weather, including extreme temperatures and natural disasters; competition; credit market conditions; cash flows; access to financing on favorable terms; future stock repurchases; the impact of recessionary conditions; consumer debt levels; changes in laws or regulations; risks associated with self-insurance; war and the prospect of war, including terrorist activity; public health issues; inflation, including wage inflation; exchange rates; the ability to hire, train and retain qualified employees, including members of management; construction delays; failure or interruption of our information technology systems; issues relating to the confidentiality, integrity or availability of information, including due to cyber-attacks; historic sales and profit growth rate sustainability; downgrade of our credit ratings; damage to our reputation; challenges associated with doing business in and expanding into international markets; origin and raw material costs of suppliers; inventory availability; disruption in our supply chain; tariffs, trade policies and other geopolitical factors; new accounting standards; our ability to execute our growth initiatives; and other business interruptions. These and other risks and uncertainties are discussed in more detail in the “Risk Factors” section contained in Item 1A under Part 1 of our Annual Report on Form 10-K for the year ended August 30, 2025. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those contemplated by such forward-looking statements. Events described above and in the “Risk Factors” section could materially and adversely affect our business. However, it is not possible to identify or predict all such risks and other factors that could affect these forward-looking statements. Forward-looking statements speak only as of the date made. Except as required by applicable law, we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:
Financial: Brian Campbell at (901) 495-7005, brian.campbell@autozone.com
Media: Jennifer Hughes at (901) 495-6022, jennifer.hughes@autozone.com

AutoZone’s 4th Quarter Highlights – Fiscal 2026
Condensed Consolidated Statements of Operations
4th Quarter, FY2026
(in thousands, except per share data)
	GAAP Results
	16 Weeks Ended				16 Weeks Ended
	August 29, 2026				August 30, 2025
Net sales	$	6,594,879			$	6,242,726
Cost of sales		3,077,151				3,026,233
Gross profit		3,517,728				3,216,493
Operating, SG&A expenses		2,200,811				2,020,428
Operating profit (EBIT)		1,316,917				1,196,065
Interest expense, net		148,684				148,087
Income before taxes		1,168,233				1,047,978
Income tax expense		236,646				211,027
Net income	$	931,587			$	836,951
Net income per share:
Basic	$	57.17			$	50.02
Diluted	$	56.05			$	48.71
Weighted average shares outstanding:
Basic		16,294				16,731
Diluted		16,620				17,181
Fiscal Year 2026
(in thousands, except per share data)
	GAAP Results
	52 Weeks Ended				52 Weeks Ended
	August 29, 2026				August 30, 2025
Net sales	$	20,338,555			$	18,938,717
Cost of sales		9,693,581				8,972,243
Gross profit		10,644,974				9,966,474
Operating, SG&A expenses		6,921,660				6,356,318
Operating profit (EBIT)		3,723,314				3,610,156
Interest expense, net		472,614				475,824
Income before taxes		3,250,700				3,134,332
Income tax expense		677,923				636,085
Net income	$	2,572,777			$	2,498,247
Net income per share:
Basic	$	156.11			$	148.80
Diluted	$	152.55			$	144.87
Weighted average shares outstanding:
Basic		16,481				16,789
Diluted		16,865				17,245
Selected Balance Sheet Information
(in thousands)
	August 29, 2026				August 30, 2025
Cash and cash equivalents	$	326,115			$	271,803
Merchandise inventories		7,735,560				7,025,688
Current assets		9,106,134				8,341,379
Property and equipment, net		8,056,120				7,062,509
Operating lease right-of-use assets		3,470,379				3,194,666
Total assets		21,630,510				19,355,324
Accounts payable		8,596,585				8,025,590
Current liabilities		10,106,530				9,519,397
Operating lease liabilities, less current portion		3,369,119				3,093,936
Total Debt		9,078,320				8,799,775
Stockholders’ deficit		(2,502,470	)			(3,414,313	)
Working capital		(1,000,396	)			(1,178,018	)

AutoZone’s 4th Quarter Highlights – Fiscal 2026
Condensed Consolidated Statements of Operations
Adjusted Debt / EBITDAR
(in thousands, except adjusted debt to EBITDAR ratio)
	52 Weeks Ended
	August 29, 2026				August 30, 2025
Net income	$	2,572,777			$	2,498,247
Add: Interest expense		472,614				475,824
Income tax expense		677,923				636,085
EBIT		3,723,314				3,610,156
Add: Depreciation and amortization		684,265				613,199
Rent expense(1)		500,020				463,031
Share-based expense		136,804				124,717
EBITDAR	$	5,044,403			$	4,811,103
Debt	$	9,078,320			$	8,799,775
Financing lease liabilities		417,328				399,940
Add: Rent x 6(1)		3,000,120				2,778,186
Adjusted debt	$	12,495,768			$	11,977,901
Adjusted debt to EBITDAR		2.5				2.5
Adjusted Return on Invested Capital (ROIC)
(in thousands, except ROIC)
	52 Weeks Ended
	August 29, 2026				August 30, 2025
Net income	$	2,572,777			$	2,498,247
Adjustments:
Interest expense		472,614				475,824
Rent expense(1)		500,020				463,031
Tax effect(2)		(203,281	)			(190,588	)
Adjusted after-tax return	$	3,342,130			$	3,246,514
Average debt(3)	$	8,884,947			$	8,948,381
Average stockholders’ deficit(3)		(2,967,742	)			(4,253,805	)
Add: Rent x 6(1)		3,000,120				2,778,186
Average financing lease liabilities(3)		415,701				396,323
Invested capital	$	9,333,026			$	7,869,085
Adjusted After-Tax ROIC		35.8	%			41.3	%
(1)The table below outlines the calculation of rent expense and reconciles rent expense to total lease cost, per ASC 842, the most directly comparable GAAP financial measure, for the 52 weeks ended August 29, 2026, and August 30, 2025.
	52 Weeks Ended
(in thousands)	August 29, 2026				August 30, 2025
Total lease cost, per ASC 842	$	673,134			$	626,625
Less: Financing lease interest and amortization		(125,127	)			(119,801	)
Less: Variable operating lease components, related to insurance and common area maintenance		(47,987	)			(43,793	)
Rent expense	$	500,020			$	463,031
(2)Effective tax rate for fiscal 2026 and 2025 was 20.9% and 20.3%, respectively.
(3)All averages are computed based on trailing five quarter balances.
Other Selected Financial Information
(in thousands)
	August 29, 2026				August 30, 2025
Cumulative share repurchases ($ since fiscal 1998)	$	40,543,302			$	38,517,689
Remaining share repurchase authorization ($)		1,606,698				632,311
Cumulative share repurchases (shares since fiscal 1998)		156,208				155,629
Shares outstanding, end of quarter		16,173				16,665
	16 Weeks Ended				16 Weeks Ended				52 Weeks Ended			52 Weeks Ended
	August 29, 2026				August 30, 2025				August 29, 2026			August 30, 2025
Depreciation and amortization	$	220,139			$	197,412			$	684,265		$	613,199
Cash flow from operations		1,183,259				990,819				3,302,846			3,155,401
Capital spending		498,769				479,698				1,496,255			1,365,321

AutoZone’s 4th Quarter Highlights – Fiscal 2026
Condensed Consolidated Statements of Operations
Selected Operating Highlights
Store Count & Square Footage
	16 Weeks Ended				16 Weeks Ended				52 Weeks Ended				52 Weeks Ended
	August 29, 2026				August 30, 2025				August 29, 2026				August 30, 2025
Domestic:
Beginning stores		6,766				6,537				6,627				6,432
Stores opened		97				91				236				196
Stores closed		–				(1	)			–				(1	)
Ending domestic stores		6,863				6,627				6,863				6,627
Relocated stores		2				4				10				9
Stores with commercial programs		6,443				6,098				6,443				6,098
Square footage (in thousands)		45,934				44,138				45,934				44,138
Mexico:
Beginning stores		933				838				883				794
Stores opened		68				45				118				89
Ending Mexico stores		1,001				883				1,001				883
Brazil:
Beginning stores		157				141				147				127
Stores opened		10				6				20				20
Ending Brazil stores		167				147				167				147
Total		8,031				7,657				8,031				7,657
Total Company stores opened, net		175				141				374				304
Square footage (in thousands)		54,661				51,818				54,661				51,818
Square footage per store		6,806				6,767				6,806				6,767
Sales Statistics
($ in thousands, except sales per average square foot)
	16 Weeks Ended				16 Weeks Ended				52 Weeks Ended				52 Weeks Ended
Total AutoZone Stores (Domestic, Mexico and Brazil)	August 29, 2026				August 30, 2025				August 29, 2026				August 30, 2025
Sales per average store	$	830			$	823			$	2,593			$	2,523
Sales per average square foot	$	122			$	122			$	382			$	374
Domestic Commercial
Total domestic commercial sales	$	1,912,981			$	1,761,960			$	5,762,414			$	5,212,294
% Increase vs. LY		8.6	%			6.0	%			10.6	%			6.7	%
Average sales per program per week	$	18.7			$	18.2			$	17.7			$	16.7
% Increase vs. LY		2.7	%			9.0	%			6.0	%			5.0	%
	16 Weeks Ended				16 Weeks Ended				52 Weeks Ended				52 Weeks Ended
Same store sales (1)	August 29, 2026				August 30, 2025				August 29, 2026				August 30, 2025
Domestic		1.6	%			4.8	%			3.3	%			3.2	%
International		10.7	%			2.1	%			13.5	%			(3.2	%)
Total Company		2.7	%			4.5	%			4.5	%			2.4	%
International – Constant Currency		1.3	%			7.2	%			2.2	%			9.3	%
Total Company – Constant Currency		1.5	%			5.1	%			3.2	%			3.9	%
(1) Same store sales are based on sales for all stores open at least one year. Constant Currency same store sales exclude the impact of fluctuations of foreign currency exchange rates by converting both the current year and prior year international results at the prior year foreign currency exchange rate.
Inventory Statistics (Total Stores)
	as of				as of
	August 29, 2026				August 30, 2025
Accounts payable/inventory		111.1	%			114.2	%
($ in thousands)
Inventory	$	7,735,560			$	7,025,688
Inventory per store		963				918
Net inventory (net of payables)		(861,025	)			(999,902	)
Net inventory/per store		(107	)			(131	)
	Trailing 5 Quarters
	August 29, 2026				August 30, 2025
Inventory turns		1.3	x			1.4	x

JERICHO, N.Y., Sept. 22, 2026 (GLOBE NEWSWIRE) — Kimco Realty^® (NYSE: KIM) will announce its third quarter 2026 earnings on Thursday October 29, 2026, before market open. You are invited to listen to our quarterly earnings conference call. The webcast information is as follows:

When: 8:30 AM ET, October 29, 2026

Live Webcast: 3Q26 Kimco Realty Earnings Conference Call or on Kimco Realty’s website investors.kimcorealty.com

Dial #: 1-833-461-5787 (International: +1 585-542-9983). Meeting ID: 639421184

Audio from the conference will be available on Kimco Realty’s investor relations website until January 27, 2027.

About Kimco Realty^®

Kimco Realty^® (NYSE: KIM) is a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States. The company’s portfolio is strategically concentrated in the first-ring suburbs of the top major metropolitan markets, including high-barrier-to-entry coastal markets and Sun Belt cities. Its tenant mix is focused on essential, necessity-based goods and services that drive multiple shopping trips per week. Publicly traded on the NYSE since 1991 and included in the S&P 500 Index, the company has specialized in shopping center ownership, management, acquisitions, and value-enhancing redevelopment activities for more than 65 years. With a proven commitment to corporate responsibility, Kimco Realty is a recognized industry leader in this area. As of June 30, 2026, the company owned interests in 564 U.S. shopping centers and mixed-use assets comprising 100 million square feet of gross leasable space.

The company announces material information to its investors using the company’s investor relations website (investors.kimcorealty.com), SEC filings, press releases, public conference calls, and webcasts. The company also uses social media to communicate with its investors and the public, and the information the company posts on social media may be deemed material information. Therefore, the company encourages investors, the media, and others interested in the company to review the information that it posts on the social media channels, including Facebook (www.facebook.com/kimcorealty), and LinkedIn (www.linkedin.com/company/kimco-realty-corporation). The list of social media channels that the company uses may be updated on its investor relations website from time to time.

CONTACT:
David F. Bujnicki
Senior Vice President, Investor Relations and Strategy
Kimco Realty Corporation
(833) 800-4343
dbujnicki@kimcorealty.com

VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) has identified a mechanical issue affecting the primary ball mill at its Guanacevi Mine.

The mill has been taken offline as of September 21, while preparations are completed to replace the mill head and trunnion, both of which are available on site. The Company expects the repairs to be completed within approximately three weeks and is coordinating with third-party service providers to expedite the replacement.

During the repair period, the regrind circuit will be configured to operate at a reduced throughput of 600 tonnes per day (tpd), compared to ordinary course capacity of approximately 1,100 tpd.

Mining operations will continue uninterrupted. The cost of replacing the affected components is expected to be minimal, as the necessary parts are already in inventory on site.

About Endeavour Silver – Endeavour is a mid-tier silver producer with three operating mines in Mexico and Peru and a robust pipeline of exploration projects across Mexico, Chile, and the United States. With a proven track record of discovery, development, and responsible mining, Endeavour is driving organic growth and creating lasting value on its path to becoming a leading senior silver producer.

Contact Information

Allison Pettit
Vice President, Investor Relations
Email: apettit@edrsilver.com
Website: www.edrsilver.com

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the United States private securities litigation reform act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking statements and information herein include but are not limited to statements regarding the suspension of processing at Guanacevi, timing for completion of repairs at the Guanacevi mill, the availability and assessment of alternative processing methods, the volume of throughput achievable through the secondary circuit, and the expected impact of this reduced capacity on Q3 production at Guanacevi. The Company does not intend to and does not assume any obligation to update such forward-looking statements or information, other than as required by applicable law.

Forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, production levels, performance or achievements of Endeavour and its operations to be materially different from those expressed or implied by such statements. Such risk factors include but are not limited to the failure to complete repairs at the Guanacevi mill in a timely manner and at the expected nominal cost, the effectiveness of alternative processing methods, adverse changes in commodity prices, greater than anticipated adverse impact on annual production levels, anticipated costs and all in sustaining costs; as well as those factors described in the section “risk factors” contained in the Company’s most recent form 40F/Annual Information Form filed with the S.E.C. and Canadian securities regulatory authorities.

Forward-looking statements are based on assumptions management believes to be reasonable, including but not limited to: the ability to complete repairs at the Guanacevi mill in a timely manner, the availability of alternative processing methods, the continued operation of the Company’s mining operations, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or information, there may be other factors that cause results to be materially different from those anticipated, described, estimated, assessed or intended. There can be no assurance that any forward-looking statements or information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information.

COCONUT CREEK, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, today announced that on September 16, 2026, it entered into a $35 million preferred stock purchase agreement with the Development Bank of Japan Inc. (“DBJ”) for 1,750,000 shares of the Company’s 8.09% Series B Preferred Stock.

“We’re delighted to continue to grow our partnership with DBJ, which started nearly 10 years ago,” said Scott B. Flaherty, Executive Vice President and Chief Financial Officer of WLFC. “It is an exciting period for the Company as we expand our global aviation services platform, including our recently announced plans for a new Willis Engine Repair Center^® in Johor, Malaysia. This additional investment from DBJ will support the continued growth of our business globally.”

Today’s announcement builds on the long-term partnership between WLFC and DBJ. In 2024, WLFC entered into a Series A Preferred Stock Purchase Agreement with DBJ, which refinanced and expanded WLFC’s $50 million of aggregate Series A-1 and Series A-2 preferred stock into one $65 million preferred stock series.

Willis Lease Finance Corporation

Willis Lease Finance Corporation leases large and regional spare commercial aircraft engines and aircraft to airlines, aircraft engine manufacturers and maintenance, repair, and overhaul providers worldwide. These leasing activities are integrated with engine and aircraft trading, engine lease pools, and asset management services through Willis Mitsui & Co. Asset Management Limited, as well as various end-of-life solutions for engines and aviation materials provided through Willis Aeronautical Services, Inc. Through Willis Engine Repair Center®, Jet Centre by Willis, and Willis Aviation Services Limited, the Company’s service offerings include Part 145 engine maintenance, aircraft line and base maintenance, aircraft disassembly, parking and storage, airport FBO and ground and cargo handling services.

Except for historical information, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties. Do not unduly rely on forward-looking statements, which give only expectations about the future and are not guarantees. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them to reflect any change in the Company’s expectations or any change in events, conditions, or circumstances on which the forward-looking statement is based, except as required by law.

The Company’s actual results may differ materially from the results discussed in forward-looking statements. Factors that might cause such a difference include, but are not limited to: the effects on the airline industry and the global economy of events such as war, terrorist activity and the COVID-19 pandemic; changes in oil prices, rising inflation and other disruptions to world markets; trends in the airline industry and the Company’s ability to capitalize on those trends, including growth rates of markets and other economic factors; risks associated with owning and leasing jet engines and aircraft; the Company’s ability to successfully negotiate equipment purchases, sales and leases, to collect outstanding amounts due and to control costs and expenses; changes in interest rates and availability of capital, both to the Company and its customers; the Company’s ability to continue to meet changing customer demands; regulatory changes affecting airline operations, aircraft maintenance, accounting standards and taxes; the market value of engines and other assets in the Company’s portfolio; and risks detailed in the Company’s Annual Report on Form 10-K and other continuing and current reports filed with the Securities and Exchange Commission. It is advisable, however, to consult any further disclosures the Company makes on related subjects in such filings. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.

CONTACT:

Scott B. Flaherty EVP & Chief Financial Officer sflaherty@willislease.com 561.413.0112

Key takeaways

• Nonhuman identities: Enterprise risk is shifting from human identity management to governing autonomous nonhuman entities.
• Browser as the unprotected workspace: More than 40% of enterprise users have installed AI-powered browser extensions, with 25% of these extensions altering permissions within 12 months.
• Chatbot interaction: More than 6% of chatbot conversations contain sensitive information.

CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) —

As organizations deploy agentic AI to execute tasks across APIs and systems, enterprises face a fundamental shift in risk. Akamai (NASDAQ: AKAM) today released its latest State of the Internet (SOTI) Security report focused on emerging AI challenges. Targeted to a CISO audience, Speed, Scale, and Nonhuman Identity: The Agentic Threat Landscape explains that securing modern business has evolved from solely identity and access management for people into a challenge of behavioral governance over nonhuman entities.

The report highlights two critical challenges: the difficulty of setting guardrails for autonomous agents, and the speed at which AI models discover vulnerabilities — often outpacing human patch cycles.

Key findings from the SOTI report

• The Model Context Protocol (MCP) visibility gap: Despite the fact that MCP (the protocol that allows AI agents to interact with multiple software systems) enables AI models to execute autonomous multisystem actions, MCP exposure ranks last among current CISO security priorities. This reveals a critical visibility gap, even as security leaders expect rogue AI agents to become a top cyberthreat by 2030.
• Chatbot data leaks: More than 6% of enterprise AI chatbot conversations contain sensitive corporate data — primarily personally identifiable information — with 47% of interactions occurring via unmonitored personal accounts.
• Exploit acceleration: Frontier AI initiatives demonstrate that models can rapidly discover and chain system weaknesses, rendering reactive patching insufficient and mandating real-time edge mitigation.
• Browser as the unprotected workspace: More than 40% of enterprise users have installed AI-powered browser extensions, with 25% of these extensions altering permissions within 12 months. These tools are 60% more likely to possess known CVEs than standard extensions.
• Rise of the synthetic customer: As AI agents replace traditional web traffic to drive brand discovery, CISOs must expand protection beyond malware to include generative engine optimization (GEO) metrics: citations, accuracy, sentiment, and bot management.

“AI presents an ‘everything, everywhere, all at once’ moment for the security ecosystem as a whole,” said Boaz Gelbord, Chief Security Officer at Akamai. “You have this triple threat: First, internal usage of AI across the organization, whether that’s AI generated code or leveraging AI productivity tools. Second, you have the integration of AI directly into customer-facing products and cloud workloads, which reshapes your operational risk profile. Third, you have AI-driven attacks targeting the enterprise. Security programs need to adapt to this rapidly evolving reality, and there’s a lot of pressure in the system due to the unprecedented speed of these changes. This is going to be a central topic for boards, customers, and regulators in the foreseeable future.”

“The rise of the agentic web marks a fundamental shift in how business value and operational logic are created,” said Steve Winterfeld, Advisory CISO of Akamai. “As autonomous AI moves from answering queries to executing multistep business strategies, security leadership must evolve alongside it.”

Strategic recommendations for security leaders

To navigate the agentic era, Akamai outlines four core pillars for CISOs in the report:

1. Shift to adaptive edge governance: Deploy edge native runtime protections, API filters, and isolation mechanisms to neutralize vulnerabilities immediately while back-end patching takes place.
2. Lock down the browser edge: Establish visibility and behavioral controls inside the browser to secure workforce adoption of unmanaged AI extensions and web-hosted models.
3. Protect brand authority in a zero-click economy: Implement GEO strategies and machine-readable data layers at the network edge to prevent AI crawlers and synthetic shoppers from hallucinating or misrepresenting corporate brand data.
4. Match autonomy to verifiability: Grant operational autonomy to AI agents based on how easily their actions can be verified and how reversible a potential failure is, maintaining human-in-the-loop controls for high-stakes actions.

Now in their 12th year, Akamai’s SOTI reports continue to offer critical insights on cybersecurity trends and web performance, drawn from attacks viewed across Akamai’s cybersecurity infrastructure, which handles a significant portion of global web traffic.

About Akamai
Akamai is the cybersecurity and cloud computing company that powers and protects business online. Our market-leading security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. Akamai’s full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. Global enterprises trust Akamai to provide the industry-leading reliability, scale, and expertise they need to grow their business with confidence. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.

Contacts
Akamai Media Relations
akamaipr@akamai.com

Akamai Investor Relations
invrel@akamai.com

The Magnum Ice Cream Company N.V.

(TMICC or the Company)

NOTIFICATION OF A TRANSACTION OF A PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR)

The Company notifies the following change in interests in the ordinary shares of EUR3.50 each (Shares) of a PDMR, arising pursuant to the grant of a share award under the 2026 Performance Share Plan (PSP). The 2026 PSP Awards was made to reflect expansion of the Chief Supply Chain Officer’s role to include Operations and are intended to reward contributions to Company performance over a sustained period and are subject to the achievement of pre-set performance conditions. The number of Shares granted was determined by taking the average closing share prices on the London Stock Exchange for the period over 14 to 18 September 2026 inclusive, being GBP14.30.

Malus and clawback provisions apply to all awards.

This announcement is made in accordance with the requirements of the EU and UK version of the Market Abuse Regulation 596/2014. 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of natural person		Sandeep Desai
2	Reason for the notification
a)	Position/status		Chief Supply Chain and Operations Officer
b)	Initial notification/Amendment		Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name		The Magnum Ice Cream Company N.V.
b)	Legal Entity Identifier code		25490052LLF3XH6G9847
4	Details of the transaction(s) summary table
	Date of Transaction	Description of Instrument		Identification Code	Place of Transaction	Currency
	21-SEP-2026	Ordinary shares of €3.50 each		ISIN: NL0015002MS2	Outside of trading venue	GBP
	Nature of Transaction	Aggregated		Price	Volume	Total
	Grant of Share Awards			14.30	5,246	75,012.55
				14.299	5,246	75,012.55

Enquiries
Media Relations media.relations-tmicc@magnumicecream.com	Investor Relations investor.relations-tmicc@magnumicecream.com

About The Magnum Ice Cream Company

The Magnum Ice Cream Company N.V. EURONEXT: MICC/ NYSE: MICC/ LSE: MICC is the world’s leading ice cream business. Home to four of the world’s five largest ice cream brands: Magnum, Ben & Jerry’s, Cornetto and the Heartbrand, our portfolio delights consumers in 80 markets around the world. Headquartered in Amsterdam, The Netherlands, we have a global team of 19,000 employees, a network of 32 factories, 13 R&D centres, and a fleet of three million freezer cabinets. For more information, visit www.corporate.magnumicecream.com. TMICC’s legal entity identifier is 25490052LLF3XH6G9847.

22 September 2026

Notification no. 75/2026

Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.

In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata.

For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Contact: Stefan Kailay Wind, Nordic Head of Media Relations, tel. +45 45 14 14 00

Attachment

• APMH Invest AS – sale – 2026 09 21

Pittsburgh, PA, Sept. 22, 2026 (GLOBE NEWSWIRE) — Alpha Compute Corp. (Nasdaq: ALP) (“Alpha Compute” or the “Company”), a vertically integrated technology pioneer in AI Confidential Compute and GPU-as-a-service (GPUaaS), today announced Alpha Compute Corp. has executed definitive real estate and asset purchase agreements in Pennsylvania.

Strategic Resource Acquisition The transaction secures over 300 acres of surface, mineral and gas rights, encompassing both the Utica and Marcellus shale formations. Historical documentation from an assessment by Haliburton estimates an average of 10,000 barrels per acre of light Pennsylvania sweet crude oil across subsurface parcels. Alpha Compute is actively conducting updated geological assessments, modern appraisals, and confirmed site reviews to precisely map reserve potential. The acquisition includes over 75 existing oil and gas wells, complete well pump jack inventories, operational maintenance facilities, heavy equipment, and associated gathering infrastructure.

“Securing these land and energy rights in Pennsylvania provides a highly resilient foundation for our next-generation compute infrastructure,” said Brittany Kaiser, CEO of Alpha Compute Corp. “We are designing this facility with the local community at the forefront of our plans. By honoring local county ordinances, adhering strictly to Pennsylvania DEP regulations, and partnering with regional grid authorities, we are ensuring that our growth creates long-term value, environmental stewardship, and clean economic development for the state.” 

Facility Design and Environmental Compliance
The planned data center will replicate the proven design, architectural framework, and community-first standards planned for Alpha Compute’s Northern Pennsylvania site. Development will comply fully with:

• Local county ordinances and land-use regulations
• Regional GRID policies and interconnection standards
• Pennsylvania Department of Environmental Protection (DEP) regulations, including applicable operator registration and bonding requirements

“Our strategy in Pennsylvania combines local energy resources with strict environmental compliance and active community participation, providing a sustainable model for technological growth. Given the USD $5.5 million acquisition price, we anticipate a substantial revaluation of the assets. Furthermore, the existing oil and gas operations are generating revenue and operational profit, with preliminary evaluations indicating that an estimated 4% of the surface oil has been extracted to date. Consequently, the site remains both profitable and financially self-sustaining,” stated Enzo Villani, Executive Chairman and President of Alpha Compute Corp.

Community Partnership and Economic Impact Alpha Compute plans to form binding covenants with local and county governments to guarantee long-term alignment with municipal development goals. The project will serve as a major regional economic engine:

• Job Creation: Projected creation of skilled permanent and construction positions;
• Infrastructure Investment: Modernization of site utilities and sustainable integration with local energy grid capacity;
• Environmental Stewardship: Post-closing environmental compliance, plugging assurances, and responsible well management under DEP oversight.

About Alpha Compute Corp. 
Alpha Compute Corp. (Nasdaq: ALP) is a vertically integrated AI infrastructure company specializing in GPU-as-a-service and AI Confidential Compute. Alpha Compute’s mission is to support clients, subsidiaries, and partners across critical sectors including: finance, defense, intelligence, and media with the essential framework for any organization requiring secure, confidential computing environments. For more information, please visit: https://www.alphacompute.ai/ 

Alpha Compute Corp is domiciled in the British Virgin Islands with offices in New York, Los Angeles, Miami, Amsterdam and Toronto. Alpha Compute is a founding partner of the Right2Compute Coalition; more information is available at www.right2compute.com

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact, including those preceded by, followed by, or incorporating words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plans,” “may,” “will,” “potential,” “continues,” or similar expressions are forward-looking statements. 

Forward-looking statements in this release include, without limitation: successful completion of the acquisition and the development and financing of the planned data center; title, acreage and net revenue interest; financing and partner arrangements; gas availability, projected power costs, well and generation plans; development, permitting, construction and commercial operation of the planned initial 200 MW facility and potential economic, environmental and community impacts. 

These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including: failure to complete the acquisition; confirmation of mineral title, recoverable resources and energy supply; permitting, environmental and well-plugging risks; the timing and progress of the Company’s strategic initiatives; reliance on third-party vendors and partners; the ability to secure additional financing; uncertainty around the Company’s investments and legacy business; risks related to technology platforms and ecosystems; and general market and economic conditions. A more complete discussion of these risks is set forth under “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2026, as amended. 

Undue reliance should not be placed on these forward-looking statements. The forward-looking statements contained herein are made as of the date of this press release, and the Company undertakes no obligation to update or revise them publicly, except as required by law. 

Investor & Media Contact 
Alpha Compute Corp. 
ir@alphacompute.ai 
www.alphacompute.ai 

CONTACT: ir(at)alphacompute.ai 

Albion Technology & General VCT PLC (the “Company”)
LEI Code: 213800TKJUY376H3KN16
22 September 2026
  
Half-yearly Financial Report for the six months to 30 June 2026

Results announcement
The Company’s Directors attach the Company’s Half-yearly Financial Report for the six months to 30 June 2026.  A summary of the information includes:

• Loss in the period of 0.83 pence per share (1.2% on opening net asset value) (30 June 2025: loss of 0.58 pence per share).
• Net asset value of 68.19 pence per share (31 December 2025: 70.71 pence per share).
• £279.0 million fund size (31 December 2025: £279.7 million).
• Dividend paid of 1.77 pence per share in the period (30 June 2025: 1.83 pence per share).

The Board also declared a second dividend for the year ending 31 December 2026 of 1.70 pence per Ordinary share to be paid on 30 October 2026 to shareholders on the register on 2 October 2026.

The Half-yearly Financial Report for the six months to 30 June 2026 is attached to this announcement. Alternatively, copies are available on the Company’s webpage on the Manager’s website at: www.albion.vc/AATG30Jun2026.

In accordance with the UK Listing Rules, a copy of the report will be submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further details about the Company please visit the Company’s webpage on the Manager’s website: www.albion.vc/vct/funds/AATG.

Vikash Hansrani
Operations Partner
AlbionVC LLP
Telephone: 020 7601 1850

Attachment

• Albion Technology & General VCT PLC Half-yearly Financial Report 30 June 2026